Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Expert faculty review and share their insights and perspectives on key findings in MDS and MPNs presented at the 2020 ASH Annual Meeting.

Share

Program Content

Activities

  • Podcast
    Expert Insights on Key Data From ASH 2020 on Myelodysplastic Syndromes and Myeloproliferative Neoplasms
    Podcast Episodes
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 05, 2021

    Expires: February 04, 2022

  • Expert Analysis
    Key Studies in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 16, 2021

    Expires: February 15, 2022

  • ClinicalThought
    Expert Selections From ASH 2020: Myelodysplastic Syndromes and Myeloproliferative Neoplasms
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 23, 2021

    Expires: February 22, 2022

Activities

CPI-0610 + RUX in MF
MANIFEST: Novel BET Inhibitor, CPI-0610, Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis Patients
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

Imetelstat in MF
Correlation of Survival and Other Clinical Benefits With Imetelstat Therapy in High-Risk, JAK Inhibitor–Refractory Myelofibrosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

HSCT in Older MDS Pts
BMT CTN 1102: RIC Allogeneic HSCT vs Non-HSCT Therapy in Patients 50-75 Yrs With Higher-risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

5-Yr RopegIFN in PV
CONTINUATION-PV: 5-Yr Results of Ropeginterferon α-2b in Polycythemia Vera
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

Expires: December 10, 2021

Pevonedistat/AZA in Higher-Risk MDS
Randomized Phase II Study of Pevonedistat Plus Azacitidine vs Azacitidine: Post Hoc Analysis in Higher-Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

DACOTA DEC vs HY in CMML
DACOTA Phase III Study of Decitabine vs Hydroxyurea for Advanced Proliferative CMML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

Roxadustat in LR-MDS
Oral Roxadustat in Anemia Secondary to Lower-Risk MDS: 1-Yr Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

Luspatercept in MF Anemia
Phase II Study of Luspatercept in RBC Transfusion-Dependent Patients With Myelofibrosis-Associated Anemia: Updated Results
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2020

Expires: December 17, 2021

Faculty

cover img faculity

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

cover img faculity

Amy Esposito, FNP-C

Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado

cover img faculity

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Supporters

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology